Hematologic Oncology | Specialty

Autologous Transplantation in Hodgkin Lymphoma

May 10th 2013

Treating Relapsed and Refractory Hodgkin Lymphoma

May 10th 2013

The Role of PET Imaging in Hodgkin Lymphoma

May 10th 2013

Primary Management of Advanced Hodgkin Lymphoma

May 10th 2013

Management of Hodgkin Lymphoma in Elderly Patients

May 10th 2013

Reducing Therapy-Related Toxicity in Hodgkin Lymphoma

May 10th 2013

Optimizing Radiation Therapy in Hodgkin Lymphoma

May 10th 2013

Risk-Adapted Approaches in Hodgkin Lymphoma

May 10th 2013

What Really Matters?

May 9th 2013

Discussing prognosis and a treatment plan has been getting particularly complicated with acute myelogenous leukemia with the development and use of molecular markers that confer prognostic and therapeutic information.

Dr. Jennifer Brown Discusses Rituximab and Ibrutinib in CLL

May 9th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the use of rituximab and ibrutinib in chronic lymphocytic leukemia.

Dr. Mesa on Ruxolitinib in Chronic Myeloid Leukemia

May 8th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.

JAK2 Inhibitor Shows Promise in Myelofibrosis

May 8th 2013

The strategy of targeting aberrant signaling in the JAK pathway appears promising thus far for SAR302503, an oral agent in development for the treatment of myelofibrosis.

Dr. Advani Discusses Front-Line Brentuximab

May 6th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Dr. Melnick on the Epigenetic Basis of B-Cell Lymphomas

May 2nd 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses his presentation on the epigenetic basis of B-cell lymphomas at the 17th International Congress on Hematologic Malignancies.

Dr. Cheson on Targeting PD-1 in Hematologic Malignancies

May 1st 2013

Bruce D. Cheson, MD, from the Georgetown Lombardi Comprehensive Cancer Center, discusses the investigation of PD-1 targeted agents as treatments for patients with lymphoma.

Dutch Researcher Focuses on Fc Signaling in Targeting CD20

April 25th 2013

Jeanette H.W. Leusen, PhD, focuses on studying the working mechanisms of therapeutic antibodies and the biology of fragment crystallizable receptors, including the anti-CD20 monoclonal antibody rituximab in patients with non-Hodgkin lymphoma.

Dr. Richard Silver Discusses the High Cost of Drugs in CML

April 24th 2013

Richard T. Silver, MD, from the New York Presbyterian-Weill Cornell Medical Center, comments on the cost of drugs to treat chronic myeloid leukemia.

Dr. Pinter-Brown on Treating CTCL With Chemotherapy

April 22nd 2013

Lauren Pinter-Brown, MD, from the University of California, Los Angeles, gives an overview of treatment with chemotherapy for patients with cutaneous T-cell lymphoma.

Dr. Advani Discusses CD30 as a Target in ALCL

April 18th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses targeting CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma.

Dr. Jennifer Brown on Ibrutinib and Idelalisib for CLL

April 17th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the treatment of chronic lymphocytic leukemia with ibrutinib, idelalisib, and other agents.